The objective of the present study was to determine the ability of 17␤-estradiol (E 2 ) and conjugated forms of E 2 (E 2 conjugated to BSA [E 2 -BSA] and a novel conjugate, E 2 conjugated to a small peptide [E 2 -PEP]) to prevent the GnRH-induced secretion of LH and to determine the role of estradiol receptors (ERs) and ER subtypes (ER␣, also known as ESR1, and ER␤, also known as ESR2) in the mediation of the acute action of E 2 in primary cultures of ovine pituitary cells. Preincubation of cells for 15 min with E 2 , E 2 -BSA, or E 2 -PEP prevented the GnRH-induced secretion of LH (P Ͻ 0.01). Treatment of cells with nonestrogenic steroid hormones did not affect secretion of LH when given alone, nor did these steroids impair the E 2 -induced inhibition of LH secretion (P Ͼ 0.1). Likewise, treatment of cells with the ERantagonists tamoxifen, hydroxytamoxifen, or ICI 182 780 did not affect (P Ͼ 0.1) secretion of LH when given alone but did prevent (P Ͻ 0.01) the inhibition by E 2 and the E 2 -conjugates on GnRH-induced secretion of LH. When cells were treated with subtype-selective ER agonists, the ER␣ agonist (propylpyrazoletriol), but not the ER␤ agonist (diarylpropionitrile), decreased (P Ͻ 0.01) the GnRH-induced secretion of LH. In conclusion, the rapidity by which E 2 prevented GnRH-induced release of LH in ovine pituitary cells suggests that this inhibition is mediated via a nongenomic action of E 2 . The inhibition of GnRH-induced secretion of LH proved to be steroid specific and mediated by ERs. It may occur specifically through ER␣. The fact that E 2 -BSA or E 2 -PEP mimicked the action of E 2 suggests that this effect was mediated by an ER associated with the plasma membrane.
INTRODUCTION
Many aspects of the positive feedback of 17␤-estradiol (E 2 ) on LH secretion have been determined [1] [2] [3] [4] ; however, the mechanisms underlying the rapid decrease in LH secretion immediately following administration of E 2 remain unknown. In vivo studies indicate that the decrease in LH secretion induced by E 2 occurs, at least in part, at the level of the pituitary gland by impairing the GnRH-induced release of LH [5] [6] [7] . Moreover, it has been proposed that the short time frame (within an hour) required for E 2 to decrease LH secretion observed in ovariectomized ewes is not compatible with the classic genomic mechanism of steroid hormone action [5] .
Estradiol conjugated to a carrier molecule, such as BSA, has been used successfully to mimic the acute (within minutes) actions of E 2 in vitro [8] [9] [10] [11] [12] [13] [14] , which implicates a nongenomic action of E 2 . Mounting evidence supports a role of E 2 -binding proteins located on the plasma membrane in mediating the acute actions of E 2 [15] [16] [17] . Several E 2 -binding proteins may be involved in mediating the acute actions of E 2 , including the primary estradiol-receptor (ER) subtypes, ER␣ (also known as ESR1) and ER␤ (also known as ESR2) [8, [18] [19] [20] [21] ; E 2 -binding to membrane proteins not related to the classic ER [22] [23] [24] [25] , such as ion channels [26] [27] [28] ; and sex hormone-binding globulin [29, 30] . Furthermore, ER␣ and ER␤ have been detected on the plasma membrane of estrogen-responsive cells [8, [18] [19] [20] [21] , and a differential [8, 9, 31, 32] , synergistic [33, 34] , or antagonistic [8, 35] action of ER␣ and ER␤ regulating cell function has been demonstrated in some cellular systems. Classically, antiestrogens, which bind to both ER␣ and ER␤ [36, 37] and generally prevent both the long-term [3, [38] [39] [40] [41] and acute actions of E 2 [10, 13, [42] [43] [44] [45] [46] , have been used to substantiate the role of ERs in mediating the actions of E 2 . Recently, a new generation of E 2 agonists that selectively activate ER␣ or ER␤ has been developed; these agonists promise to be important tools for identifying the role of specific ER subtypes in mediating actions of E 2 [39, [47] [48] [49] [50] [51] . The present study was conducted to examine the ability of E 2 and conjugated forms of E 2 to rapidly prevent the GnRH-induced secretion of LH and to determine which ER subtype is responsible for mediating the acute action of E 2 in ovine pituitary cells.
MATERIALS AND METHODS

Conjugation of E 2 to an Amino Acid Sequence
Six-keto-17␤-estradiol-6-carboxy methyl oxime (E 2 -6-CMO; Steraloids, Inc., Newport, RI) was conjugated to the amino group of serine of a 15-amino acid sequence (N-terminus-SGGEVVVDQPMERLY-C-terminus; PEP; Macromolecular Resources, Colorado State University, Fort Collins, CO). The E 2 -6-CMO was chosen to prepare a conjugate, because derivatization at carbon 6 of E 2 does not prevent interaction of receptors with the hydroxyl radicals at positions 3 and 17 [52] [53] [54] . The reactions were performed at 10ЊC and pH 8 using N,N-dimethylformamide (DMF) as solvent [55] as follows: 4 mmol of E 2 -6-CMO dissolved in 0.5 ml of DMF were allowed to react for 10 min with 4 mmol of tri-N-butylamine, then 4 mmol of isobutyl chloroformate was added and the reaction continued for 20 min. Finally, 2 mmol of PEP were dissolved in DMF and mixed with the other reagents, and the reaction was continued for an additional 60 min before termination by the addition of approximately 10 l of 0.1 M acetic acid.
Purification of E 2 -PEP Conjugate
Conjugation reactions were added to a 50-ml Sephadex LH20 column (Sigma, St. Louis, MO) using methanol as solvent. Twenty-five fractions (2 ml each) were collected. Presence of reactants was determined by optical densitometry at a wavelength of 280 nm. Identification of the reactants in the eluate was determined by Mass Spectrum Analysis (Macromolecular Resources) using two different procedures: Matrix Assisted Laser Desorption Ionization Time of Flight for compounds with an M r of greater than 1000 (free PEP and E 2 -PEP conjugate), and electrospray mass spectrometry for compounds with an M r of less than 500 (free E 2 -6-CMO). Conjugation efficiency was calculated based on the amount of unconjugated E 2 -6-CMO after separation of reactants by chromatography. The weight of unconjugated E 2 -6-CMO was estimated by plotting the absorbency values against those from known amounts of E 2 -6-CMO.
The E 2 -BSA (ϳ30 molecules of E 2 attached to each molecule of BSA) was purchased from Steraloids. To remove free E 2 , approximately 20 mg of E 2 -BSA were dissolved in 2 ml of PBS in a 16-ϫ 150-mm glass tube. Five milliliters of diethylether were added, and the contents of the tubes were vortexed for 1 min and then frozen in dry-ice methanol. The organic fraction was poured into a 12-ϫ 75-mm glass tube and evaporated under nitrogen in a warm heating block. Dried extracts were reconstituted in PBS containing 0.1% gel, incubated at 4ЊC overnight, and vortexed before quantification of E 2 by radioimmunoassay. The extraction procedure was repeated six times for each sample, and each extract was kept separate and assayed for free E 2 [56] .
Preparation of Media and Stock Solutions
Pituitary dissociation medium consisted of 137 mM NaCl, 5 mM KCl, and 25 mM Hepes (U.S. Biochemical Corp., Cleveland, OH), pH 7.3, plus an enzymatic cocktail containing 1.0 mg/ml of collagenase (type II), 1.0 mg/ml of hyaluronidase (type V), and 0.02 mg/ml of deoxyribonuclease. Enzymes were freshly prepared immediately before dissociation. Culture medium consisted of Dulbecco modified Eagle medium (DMEM; SigmaAldrich, Inc., Saint Louis, MO) supplemented with 10% ovariectomized ewe serum, 500 mg/ml of streptomycin sulfate, 313 mg/ml of potassium penicillin G, and 2.2 g/L of NaHCO 3 . Dissociation and culture medium, as well as the enzymatic cocktail, were sterilized by filtration through 0.2-m Millipore membranes (Fisher Science LLC, Denver, CO). Stock solutions of GnRH (in saline solution plus 0.1% BSA), E 2 -BSA, or E 2 -PEP (both in saline solution) were stored at Ϫ20ЊC in small aliquots. Steroid hormones were purchased from Sigma-Aldrich, and antagonists and agonists of ERs were purchased from Tocris Cookson, Inc. 
Dissociation and Incubation of Pituitary Cells
All procedures involving animals were approved by the Colorado State University Animal Care and Use Committee and complied with National Institutes of Health (NIH) guidelines. Anterior pituitary glands were collected during the breeding season following anesthesia of ewes with sodium pentobarbital and exsanguination. Tissues were removed and immediately placed in ice-cold dissociation medium. Anterior pituitary tissue from ovariectomized ewes was dispersed as described by Adams et al. [57] with the omission of trypsin digestion. Briefly, tissue was sectioned (thickness, 0.5 mm) with a Stadie-Riggs tissue slicer (Thomas Scientific, Swedesboro, NJ) and washed five times with dissociation medium without enzymes. Tissue was incubated in dissociation medium containing the enzymatic cocktail at 37ЊC in a Dubnoff metabolic shaker (GCA/Precision Scientific, Winchester, VA) for 90 min, and every 30 min, the cell suspension was passed through a Pasteur pipette. After dissociation, the cell suspension was washed (400 ϫ g, 4 min) five times with dissociation medium without enzymes, resuspended in DMEM, and plated at 2 ϫ 10 5 cells/well in 24-well tissue culture plates (Becton Dickinson Co., Franklin Lake, NJ). Cells were incubated for 2 days at 37ЊC under an atmosphere of 95% air:5% CO 2 . Cell viability was evaluated immediately after tissue dissociation and before administration of treatments by incubating the cells with 1% trypan blue for 3-4 min.
The amount of LH released from primary cultures of ovine pituitary cells [58] and the amount of free E 2 extracted from E 2 -BSA [59] were quantified by a double-antibody radioimmunoassay. The reference standard for LH was NIH-OLH-S24. Triplicate standard curves were included in each assay, and samples were analyzed in duplicate at 50 and 100 l sample/tube for LH and E 2 , respectively. Intra-and interassay coefficients of variation for LH were 3% and 7%, respectively, and the minimum detectable dose of LH averaged 28 pg. Intra-and interassay coefficients of variation for E 2 were 5% and 10%, respectively, and the minimum detectable dose of E 2 averaged 0.5 pg.
Experimental Procedure
The experiments were performed to evaluate the acute effects of conjugated or unconjugated forms of E 2 on GnRH-induced release of LH, the steroid specificity of E 2 actions, and the involvement of ERs as well as to determine which ER subtype is responsible for mediating the acute effect of E 2 in primary cultures of ovine pituitary cells. After 2 days of incubation, anterior pituitary cells were washed twice with culture medium, and treatments were applied in 1 ml of medium. Cells (2 ϫ 10 5 cells/ well, four wells per treatment, and three replicates [pituitaries] per experiment) were preincubated for 15-60 min with the corresponding treatment. After preincubation, cells were washed once with medium and incubated for 15 min with culture medium (negative control) or the previous treatment plus 2 nM GnRH. The dose of GnRH used in the present study is within the minimum dose that induces maximal release of LH in culture ovine pituitary cells as reported previously [57] . Culture medium was collected, centrifuged at 400 ϫ g for 5 min to remove cells, transferred (ϳ90% of medium) to a 12-ϫ 75-mm plastic culture tube, and stored at Ϫ20ЊC for quantification of LH. When ethanol was used as solvent, its final concentration in the culture medium was never more than 0.1%, and the addition of 0.1% of ethanol to the GnRH-treated cells did not affect the amount of LH released. Experiment 1. To evaluate the effect of E 2 , E 2 -BSA, and E 2 -PEP on GnRH-induced release of LH, anterior pituitary cells were preincubated for 60 min with 0, 0.01, 0.1, 1, 10, or 100 nM E 2 , E 2 -BSA, or E 2 -PEP. After preincubation, cells were washed and incubated for 15 min with culture medium or the previous treatment of E 2 , E 2 -BSA, or E 2 -PEP plus 2 nM GnRH.
Experiment 2. The effect of preincubation time on the ability of conjugated or unconjugated forms of E 2 to decrease the amount of LH released during a subsequent 15-min GnRH challenge was analyzed by preincubating the cells for 15, 30, or 60 min with 0-100 nM E 2 , E 2 -BSA, or E 2 -PEP. The experiment was conducted in two parts. In the first, dispersed pituitary cells were preincubated for 30-60 min (control group); in the second part, cells were incubated for 15-60 min (control group).
Experiment 3. To evaluate the effect of nonestrogenic steroid hormones and an E 2 stereoisomer (␣E 2 ) on GnRH-induced release of LH, cells were preincubated for 15 min with 0 or 1 nM E 2 or 100 nM P 4 , T, HC, or ␣E 2 with and without 1 nM E 2 . After preincubation, cells were treated with GnRH as described above.
Experiment 4. To study the ability of E 2 antagonists to prevent the inhibitory action of E 2 on the release of LH induced by GnRH, cells were preincubated for 15 min with 0 or 1 nM E 2 or 100 nM Tx, HTx, or ICI with and without 1 nM E 2 , E 2 -BSA, or E 2 -PEP. After preincubation, cells were treated with GnRH as described above.
Experiment 5. The ability of specific ER (␣ and ␤) agonists to mimic the action of E 2 on secretion of LH was determined by preincubating the cells for 15 min with 0, 0.01, 0.1, 1, 10, or 100 nM PPT or DPN. After preincubation, cells were treated with GnRH as described above.
Data Analysis
Data were subjected to ANOVA using the general linear model of SAS [60] in a completely randomized design. When a significant F-value occurred, means were separated using Fisher least significant difference adjusted by the Tukey procedure. Data are presented as mean Ϯ SEM throughout.
RESULTS
Chromatography of the reactants subjected to conjugation revealed two major peaks in fractions collected from the Sephadex LH20 column (Fig. 1) . Mass Spectrum Analysis revealed two main compounds in fractions 9-11, one with an M r of 1679, corresponding to unconjugated PEP, and another with an M r of 2020, corresponding to E 2 -PEP conjugate. The main compound detected in fractions 13 and 14 had an M r of 359, corresponding to unconjugated E 2 -6-CMO. Efficiency of the individual conjugations ranged from 20% to 100% (n ϭ 10) and averaged 44% Ϯ 22%.
Extraction with diethyl ether removed 0.7% (15.12 Ϯ 4.02 g of E 2 , n ϭ 3 independent extractions of conjugate) FIG. 1. Two peaks were detected by optical densitometry in fractions collected after Sephadex LH20 column chromatography of the reaction mixture. Mass Spectrum Analysis revealed two compounds in fractions 9-11, one with a molecular weight of 1679, corresponding to free PEP, and another with a molecular weight of 2020, corresponding to E 2 -PEP. The major compound detected in fractions 13 and 14, with a molecular weight of 359, corresponded to free E 2 -6-CMO. of total expected E 2 (at a 30:1 ratio) present in 20 mg of E 2 -BSA powder. The amount of free E 2 represented less than 1% of the weight of the conjugate.
The dissociation procedure yielded 76.5 Ϯ 0.41 ϫ 10 6 cells per pituitary (n ϭ 12). Viability of pituitary cells after tissue dissociation was always greater than 95% (96.4% Ϯ 0.6%, n ϭ 12). After incubation for 2 days, cell viability was always greater than 80% (86.2% Ϯ 1.1%, n ϭ 12).
For experiment 1, incubation of anterior pituitary cells with 2 nM GnRH for 15 min increased the release of LH compared with that in untreated cells (53.11 Ϯ 2.46 versus 3.3 Ϯ 2.01 ng/ml, P Ͻ 0.01). Treatment with E 2 ( Fig. 2A) , E 2 -BSA (Fig. 2B) , or E 2 -PEP (Fig. 2C) inhibited (P Ͻ 0.01) GnRH-induced release of LH in a dose-dependent manner. For E 2 -treated cells, 0.1 nM E 2 decreased release of LH compared to cells treated with GnRH only, but 10 nM E 2 was required to abolish completely the GnRH-induced release of LH ( Fig. 2A) . Similarly, 0.1 nM E 2 -BSA (Fig. 2B ) or E 2 -PEP (Fig. 2C ) decreased that release of LH compared to that in cells treated with GnRH only, and as with E 2 , 10 nM of each conjugate was required to abolish completely the GnRH-induced release of LH.
In were preincubated for 15 min with culture medium and 1 nM E 2 or 100 nM of one of the following E 2 antagonists: Tx, HTx, or ICI. Culture medium was aspirated and cells incubated for 15 min with culture medium containing the previous treatment plus 2 nM GnRH or culture medium. B. Cells were treated as described in A, but 1 nM E 2 was added to cells treated with antagonists during the 15-min challenge with GnRH. C. Cells were treated as described in B, but E 2 -BSA replaced E 2 . D. Cells were treated as described in B, but E 2 -PEP replaced E 2 . Data represent the average of three pituitaries and three or four wells per treatment per pituitary and are presented as the mean Ϯ SEM. Comparisons were among controls versus treatments. Bars with unlike letters differ (P Ͻ 0.01).
between treatment (E 2 , E 2 -BSA, or E 2 -PEP) and dosage (P Ͼ 0.1) were found. Therefore, treatments were pooled by dosage, and the interaction of treatment with preincubation time was analyzed.
In experiments 3-5, incubation of anterior pituitary cells with 2 nM GnRH for 15 min increased the release of LH compared with that in untreated cells (33.5 Ϯ 2.6 vs. 18.76 Ϯ 2.6 ng/ml, P Ͻ 0.01). In these cells, treatment with steroid hormones (100 nM P 4 , T, HC, or ␣E 2 ) did not affect the GnRH-induced release of LH (Fig. 4A) . Moreover, when pituitary cells were coincubated with these steroids plus E 2 , they did not (P Ͼ 0.1) alter the inhibition of GnRH-induced release of LH caused by 1 nM of E 2 (Fig.  4B) . Similarly, treatment of pituitary cells with E 2 antagonists did not (P Ͼ 0.1) influence the GnRH-induced release of LH (Fig. 5A) . However, ER antagonists prevented the inhibition of GnRH-induced release of LH induced by 1 nM E 2 (P Ͻ 0.01) (Fig. 5B ), E 2 -BSA (P Ͻ 0.1) (Fig.  5C) , or E 2 -PEP (P Ͻ 0.1) (Fig. 5D) . The selective ER␣-agonist PPT decreased (P Ͻ 0.01) the release of LH in response to a GnRH challenge, but only at a concentration of 100 nM (Fig. 6A) , whereas the selective ER␤-agonist DPN did not decrease GnRH-induced release of LH at the concentrations tested (Fig. 6B) .
DISCUSSION
Conjugation of E 2 -6-CMO to a 15-amino acid sequence yielded a biologically active, conjugated form of E 2 free of unconjugated E 2 . The 1:1 ratio of E 2 to carrier molecule, together with the presence of a tyrosine residue at the Cterminal position in the PEP, makes this novel E 2 conjugate suitable for biological studies. It provides a preferable alternative to E 2 -BSA, because only one molecule of E 2 can be linked to the PEP. Thus, when performing kinetic analyses, only one molecule of ER can interact with the E 2 -PEP. In the case of E 2 -BSA, at least theoretically, it may be possible for several ERs to bind to a single E 2 -BSA because of the multiple molecules of E 2 attached to each BSA. This would complicate its use for any kinetic analysis.
Steroid-BSA conjugates have been reported to contain unbound or adsorbed steroid in the range of 1-4% [55, 61] of the weight of the conjugate. In the present study, less than 1% of the weight of the conjugate was removed as free E 2 from the commercial E 2 -BSA by solvent extraction. The amount of free E 2 remaining in the E 2 -BSA conjugate after the sixth extraction was substantially less than the concentration needed to elicit a physiological response.
In the first experiment, preincubation of pituitary cells for 60 min with E 2 resulted in a dose-dependent inhibition of GnRH-induced release of LH. The 0.1 nM E 2 resulted in a significant decrease (P Ͻ 0.01) in GnRH-induced release of LH, but 10 nM E 2 was required to suppress completely the release of LH. This finding is consistent with other reports in which E 2 concentrations in the range of 0.1-10 nM have been used successfully to modulate signaling pathways in hypothalamus [43] , endothelial cells [19] , adipocytes [12] , neurons [14] , and a pituitary tumor cell line [62, 63] . Similarly, 10 nM of either E 2 -BSA or E 2 -PEP completely prevented GnRH-induced release of LH. Likewise, 1-10 nM E 2 -BSA has been used successfully to mimic acute actions of E 2 in vitro [8] [9] [10] [11] [12] [13] [14] 18] .
Because of the limited number of dispersed cells obtained from ovine pituitaries, evaluation of the effect of preincubation time (15, 30 , or 60 min) on inhibition of LH secretion induced by free or conjugated E 2 was performed in separate experiments. A 60-min preincubation time was used in each experiment to serve as a basis for comparison. Preincubation of pituitary cells with E 2 or its conjugated forms for 15, 30, or 60 min induced a similar dose-dependent inhibition of GnRH-induced release of LH. However, the amount of LH released by GnRH in pituitaries used to compare 15 min versus 60 min of preincubation time was approximately 25% the amount of LH released by GnRH in previous experiments (compare positive controls in Fig.  3, A and B) . In these less responsive pituitaries, basal levels of LH were threefold higher than the basal levels of LH detected in the more sensitive cells. Although a lack of or reduced responsiveness to physiological secretogogues (thought to result from enzyme-induced receptor damage) is commonly observed in enzymatically dissociated secretory cells [64, 65] , it has been demonstrated that ovine pituitary cells recover their ability to secrete LH in response to GnRH from 16 to 24 h after enzymatic dispersion [57] . In the present study, cells were cultured for 48 h before challenge with GnRH; therefore, potential damage to GnRH receptors may not be the overriding cause for the low sensitivity to GnRH. Whatever the reason for the low sensitivity to GnRH, it is reasonable to assume that the high basal levels of LH decreased the amount of LH stored in pituitary cells, resulting in poor release of LH in response to GnRH.
As mentioned above, preincubation of pituitary cells with E 2 or its conjugated forms for 15, 30, or 60 min induced a similar dose-dependent inhibition of GnRH-induced release of LH. Therefore, it appears that only one molecule of E 2 on the E 2 -BSA conjugate interacts with ER. In several studies, treatment with E 2 or E 2 -BSA over a wide range of intervals (1-40 min) modulated a variety of signaling pathways, including cGMP production [44] , activation of extracellular signal-related kinase (ERK) [9, 12] , nitric oxide synthase (NOS) [18] , and Akt [10] , among others. Therefore, our data support the concept that in ovine pituitary cells, E 2 acutely suppresses the GnRH-induced release of LH by a nongenomic mechanism. In this regard, several studies have indicated that E 2 -BSA, distinct from E 2 , did not stimulate reporter activity in cells transfected with ERE-luciferase reporter constructs [8, 11, 45, 46] , further suggesting that E 2 -BSA acts through a nongenomic mechanism. Moreover, the novel E 2 -PEP proved to be active biologically and to mimic the acute suppression of GnRH-induced secretion of LH by E 2 .
As in the last group of experiments, the sensitivity of pituitary cells to a GnRH challenge also was lower and accompanied by higher basal levels of LH compared with the more responsive cells used in the first experiment. Treatment of pituitary cells with E 2 , E 2 -BSA, or E 2 -PEP did not induce the smooth, dose-dependent inhibition of GnRH-induced release of LH observed in more sensitive cells; instead, a sudden decrease in LH release to the media was detected at 1 nM unconjugated or 10 nM conjugated E 2 , respectively. As expected, incubation of these pituitary cells with a 100-fold excess of P 4 , T, HC, or the stereoisomer ␣E 2 did not mimic the acute inhibition of E 2 on GnRHinduced release of LH. This suggests that inhibition of GnRH-induced release of LH is a specific action of E 2 and agrees with previous results in which other steroid hormones failed to mimic the acute actions of E 2 on activation of NOS [43, 66] and several protein kinases [9, 12, 14, 46, 67, 68] as well as cAMP production [69] . Furthermore, in the present study, addition of a 100-fold excess of the steroid hormones tested did not alter the inhibition by E 2 of the GnRH-induced release of LH, further supporting the specificity of this effect. Similarly, in most studies ␣E 2 did not activate signaling pathways acutely stimulated by E 2 [9, 12, 19, 67, [69] [70] [71] .
A 100-fold excess of antiestrogens completely prevented the inhibition of GnRH-induced secretion of LH by E 2 , providing further support for the hypothesis that the acute action of E 2 occurs via ERs; numerous others have reported that Tx, HTx, and ICI prevented the acute action of E 2 on modulation of signaling pathways, including activation of NOS [ and tyrosine kinases [73, 76] as well as phosphorylation of transcription factors [9, 12, 76, 78] . The fact that antiestrogens did not cause an acute effect on cellular response when administered alone also agrees with previous reports [42, 66, 70] and further supports the idea that binding of ERs to these compounds prevents their occupancy by E 2 , resulting in a rapid antagonistic action. Likewise, in the present study, antiestrogens prevented the inhibition of GnRH-induced release of LH by conjugated forms of E 2 , suggesting a plasma membrane location of ERs. An antagonistic action of Tx and ICI on the mimetic action of E 2 -BSA in signaling pathways rapidly activated by E 2 have been reported. For example, the rapid release of nitric oxide by E 2 -BSA from median-eminence fragments was prevented by Tx [43] ; moreover, the E 2 -BSA-induced phosphorylation of MAP kinases was prevented by ICI [9, 11, 12] .
It has been proposed that in some cells, acute actions of E 2 in cellular function may be mediated by a binding protein that is different from the common ER␣ and ER␤ [25, 79, 80] . In this scenario, ICI appears to behave atypically, and this has been interpreted to suggest interaction with a novel binding protein [14, 25, 81] . For example, in immature neural cells, ICI mimicked the acute actions of E 2 on cAMP/protein kinase A activation [81] and phosphorylation of ERK 1/2 [14] , whereas in neural cells from mice lacking ER, ICI did not antagonize the acute actions of E 2 on ERK phosphorylation [80] or the E 2 -induced potentiation of kainate currents [81] . Interestingly, when ICI behaved atypically, ␣E 2 also mimicked actions of E 2 [14, 81] .
The role of ER subtypes in mediating inhibition of GnRH-induced release of LH by E 2 was further evaluated by using selective agonists for ER␣ or ER␤. Our data agree with previous observations implicating ER␣ in the mediation of the acute inhibition induced by E 2 . The selectiveagonists PPT and DPN selectively recruit coactivators via ER␣ or ER␤, respectively [49] ; however, their ability to mimic acute actions of E 2 has just begun to be investigated. In a recent study, PPT acutely mimicked the vasodilatory action of E 2 in mesenteric arteries; however, when DPN was given at pharmacological concentrations, it also had a lesser, but significant, effect on vasodilation [82] . Because there appeared to be a slight effect of DPN on the inhibition of GnRH-induced LH secretion at the highest concentration tested, similar findings might have occurred in the present study if we had used even higher concentrations of DPN.
In conclusion, the rapidity by which E 2 prevented GnRH-induced release of LH in cultured ovine pituitary cells supports the concept that this effect is mediated by a nongenomic action of E 2 . The inhibitory action of E 2 , E 2 -BSA, or E 2 -PEP in secretion of LH proved to be steroid specific and equally sensitive to blockade by E 2 antagonists. These data indicate that ERs mediate the acute inhibitory action of E 2 on secretion of LH. The presumed impermeability of conjugated forms of E 2 suggests a plasma membrane location of ERs mediating the rapid inhibition of LH secretion. Moreover, the use of selective ER agonists indicates that acute inhibition of GnRH-induced release of LH by E 2 may occur via ER␣.
